Damayanti Kerai · HSBC
directClarify margin outlook: 18% by Q2 and 20%+ for full year?
No, I never said. For the year is 18% plus special product. I made it very clear. Excluding that, I will be targeting around 18% for the year.
AUROPHARMA / Q1-FY24 / claim-ledger
Audit the questions that mattered.
Aurobindo Pharma · Analyst questions, management answers, and the quality of the response where the ledger is available.
Research layer active
ConCallIQ research layer
Signal, with the source still visible.
Use the controls below to narrow the view, then follow the evidence into the next layer of context.
Questions audited
12
Answered directly
79%
Numeric claims
10
Consistency
mixed
Question ledger
What was answered, and how?
Damayanti Kerai · HSBC
evasiveWhat is changing in Eugia vertical restructuring?
We are now planning to start the process. How it will take a shape, we'll come to know maybe in the next one or two months. The decision has been taken only day before, I mean, on 12th of August only, we'll come to know it clearly in the next two, three months.
Neha Manpuria · Bank of America
directWhy did US oral solid growth not reflect in gross margins? Impact of Puerto Rico shutdown?
The 0.6% drop is attributed to the drop in the export benefits. It's a timing issue. Puerto Rico, practically we are having a zero EBITDA, with a shutdown and restructure. We are likely to see a EBITDA margin improving by 0.5%.
Neha Manpuria · Bank of America
directWhat is the quarterly sales contribution of Puerto Rico to US business?
Typically, they contribute around, in and around 15%-20%, anywhere between 15%-20%. Last year as a whole, if I recollect, our contribution for the last year was around $52 million.
Shyam · Research desk
partialWhat is the outlook for US base business and pricing erosion? Also Revlimid opportunity.
We had a volume-led strategy in the US, and we have delivered strong underlying growth. I would say the prices are stable now. We have seen continuation of that.
Shyam · Research desk
directWhat is the non-US global Eugia growth quarter-on-quarter and drivers?
It's basically like, we used to be in the midst of around $100 million-$110 million for last few quarters. That has gone up to $122 million now. Our endeavor is to grow that business to $130+ million, starting from next quarter.
Kunal Dhamesha · Macquarie Group
directIs the $500M Eugia guidance excluding Revlimid? What happened to $650-700M guidance?
I stopped giving that guidance that was given 2 years back. We will treat these as two different things. One is how do we grow the base business. That is the 500, how we can go to 550 and on, plus Revlimid.
Kunal Dhamesha · Macquarie Group
partialIs the 18% EBITDA margin guidance based on flat pricing assumption?
As on date, it is 16.8%. With the export benefits coming back, which will add to another 0.5%. Puerto Rico will add another 0.5%. If you really see the adjusted EBITDA, it's already 17.8%.
Surya Patra · PhillipCapital
partialIs the strong injectable quarter sustainable? What is driving it?
It's a decent start for the year, we expect that it will ramp up further. It has nothing to do with the current shortages. It is a general growth in volumes and H2 launches.
Surya Patra · PhillipCapital
directWhat is the margin level for European business now?
We have reached mid-teens in EBITDA % to net sales.
Bino Pathiparampil · Elara Capital
directWhen will generic Opsumit and Myrbetriq be launched?
Opsumit, it's a tentative approval, under settlement. The launch would take some time. Next financial year? No, we don't believe so. It could be sometime later. Mirabegron also will have a subsequent launch.
Tarang Agrawal · Old Bridge Asset Management
directWhat is Eugia's volume share in US injectables and how has it moved?
We are growing by around 10% volume. We have reached in US, in the injectable segment, to the 6th position. We used to be around nine, then we reached seven, now we are, as per latest figures, we reached 6th.